Friday, March 27, 2015
Valneva announces approval of an EB66-based prototype influenza vaccine in Japan.
Vaccine was developed by Chemo-Sero Therapeutic Research Institute (Kaketsuken) in collaboration with GlaxoSmithKline using Valneva's EB66 cell line.
Says this represents a potential of 80 million vaccine doses to be produced in the event of a pandemic.
reuters.com
